← Back to patent-cliff list
DSP-2230
Tier C — Watch / tradeDSP-2230
Sumitomo Dainippon Pharma Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Nav1.7, Nav1.8
Indications (approved)：神经痛
Regional status
US
-
EU
-
China
-
Japan
Phase II
2021-01-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DSP-2230?
Approved indications include: 神经痛.
When does the DSP-2230 patent expire?
No public expiry year is available for DSP-2230 yet; this page updates once verified.
How do I get a quote for DSP-2230 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06